Reslizumab is a humanized IL-5 antagonist IgG4κ monoclonal antibody approved by the FDA and EMA as an add-on maintenance treatment for patients aged 18 years and older with severe asthma and an eosinophilic phenotype [33,34]. This evidence concerns the gene IL5 and asthma.